CXCL8 and rheumatoid arthritis: ABX-IL8, a fully humanized monoclonal anti-CXCL8 antibody produced by Abgenix using XenoMouse technology has been assessed in clinical trials for rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD).